Episode # 43 • 13 Jan 2026
ESMO Update: Trial Results & New Therapies in Colorectal Cancer
Get caught up on the cutting edge colorectal cancer trial data from ESMO 2025 with this 30-minute BackTable Tumor Board recap! Featuring medical oncologists Dr. Jonothan Mizrahi and Dr. Jun Gong.
Timestamps
00:00 - Introduction
01:25 - Overview of ESMO 2025 Annual Congress
13:50 - cTDNA Monitoring in Clinical Practice
16:24 - STELLAR-303 Study: Immunotherapy in MSS Colorectal Cancer
20:40 - Neoadjuvant Immunotherapy for MSI High Colorectal Cancer
26:39 - DESTINY-CRC02 Study: Final Analysis
29:30 - Conclusion and Outro
Resources
You may also like
More about this episode
The doctors discuss the DESTINY-CRC02 trial with focus on HER-2 positive metastatic colorectal cancer, the DYNAMIC-III and Pegasus studies regarding CTDNA-guided therapies, and the pivotal STELLAR-303 study for treatment-refractory microsatellite stable colorectal cancer. They also review the implications of NICHE-2 and FOxTROT studies on neoadjuvant chemotherapy versus immunotherapy for MSI high patients. Emphasis is placed on the real-world practice applications of these study findings, potential treatment shifts, and how these new trial results will impact future guidelines in colorectal cancer care.
The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.